Clinical Trials Logo

Filter by:
NCT ID: NCT02923921 Completed - Pancreatic Cancer Clinical Trials

Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer

Sequoia
Start date: March 1, 2017
Phase: Phase 3
Study type: Interventional

To compare the efficacy of pegilodecakin in combination with FOLFOX versus FOLFOX alone in participants with metastatic pancreatic cancer as measured by overall survival.

NCT ID: NCT02923115 Completed - Pulmonary Embolism Clinical Trials

Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism

Start date: June 23, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1b, double-blind (participants and Investigators), placebo-controlled, randomized, single-ascending dose, multi-center study to assess the safety, efficacy, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DS-1040b in participants with acute submassive pulmonary embolism.

NCT ID: NCT02922205 Completed - Observational Clinical Trials

Stapler Post-market Observational Study

Start date: April 6, 2017
Phase:
Study type: Observational [Patient Registry]

The purpose of this observational study is to evaluate the safety and performance of the Endoscopic Linear Cutter Stapler and reloads from Fengh Medical used in laparoscopic Roux-en-Y gastric bypass surgery to create anastomoses. The goal of the study will be achieved by assessing the device performance and reporting of peri- and postoperative complications in a prospectively maintained database.

NCT ID: NCT02921971 Completed - Systemic Sclerosis Clinical Trials

Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis

Start date: December 21, 2016
Phase: Phase 2
Study type: Interventional

Primary Objective: To evaluate, in comparison with placebo, the efficacy of SAR156597 administered subcutaneously for 24 weeks on skin fibrosis in participants with diffuse cutaneous systemic sclerosis (dcSSc). Secondary Objectives: - To evaluate the efficacy of SAR156597 compared to placebo on physical/functional disability in participants with dcSSc. - To evaluate the efficacy of SAR156597 compared to placebo on respiratory function of participants with dcSSc. - To evaluate the safety profile of SAR156597 compared to placebo in participants with dcSSc. - To evaluate the potential for immunogenicity (anti-drug antibodies response) of SAR156597 in participants with dcSSc. - To evaluate the pharmacokinetics (trough plasma concentrations) of SAR156597 administered subcutaneously for 24 weeks.

NCT ID: NCT02921854 Completed - Clinical trials for Non Small Cell Lung Cancer

Detection of Circulating Biomarkers of Immunogenic Cell Death

ICD
Start date: April 4, 2017
Phase: N/A
Study type: Interventional

In this exploratory study, the investigators will investigate if markers (molecular and immunological) of ICD or anti-tumor immunity (exosomal or molecular) can be detected in the serum of patients after high-dose radiotherapy alone or concurrent cisplatin-doublet therapy and radiotherapy. For each patient: withdraw blood at three times during treatment for analysis.

NCT ID: NCT02920827 Completed - HIV Infections Clinical Trials

Safety and Pharmacokinetic Trial in Healthy HIV-Negative Women to Assess the Delivery of Dapivirine From a Vaginal Ring

Start date: August 2009
Phase: Phase 1
Study type: Interventional

The proposed study is a single center, double-blind placebo-controlled trial to assess the safety and tolerability of the dapivirine ring as compared to a placebo ring when inserted for 28 days in 16 healthy, HIV-negative women.

NCT ID: NCT02920463 Completed - Infection Clinical Trials

DetermInants of Antimicrobial Use aNd De-escalAtion in Critical Care (DIANA)

DIANA
Start date: October 1, 2016
Phase:
Study type: Observational

DetermInants of Antimicrobial use aNd de-escalAtion in critical care (DIANA study), is a multicenter, international, prospective, observational cohort study, aiming to describe the rate of de-escalation as well as the associated outcome and the empirical antibiotic therapy for infections at the intensive care unit.

NCT ID: NCT02920008 Completed - Clinical trials for Acute Myeloid Leukemia

Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia

Start date: March 16, 2017
Phase: Phase 3
Study type: Interventional

Multicenter, randomized, open-label, parallel-group study of guadecitabine vs treatment choice (TC). Participants will be randomly assigned in a 1:1 ratio to either guadecitabine or TC. TC options include the 8 high or low intensity, locally available regimens below; or Best supportive Care (BSC) alone: - High intensity (intermediate or high dose cytarabine [HiDAC]; mitoxantrone, etoposide, and cytarabine [MEC]; or fludarabine, cytarabine, granulocyte colony stimulating factor [G-CSF], +/- idarubicin [FLAG/FLAG-Ida]). - Low intensity (low dose cytarabine [LDAC], decitabine, or azacitidine). - BSC.

NCT ID: NCT02918695 Completed - Multiple Myeloma Clinical Trials

Comparison of Geriatric Screening Methods in Newly Diagnosed Multiple Myeloma Patients

COMPASS
Start date: April 7, 2017
Phase:
Study type: Observational

The purpose of this study is to compare clinical judgment and comprehensive geriatric assessment as screening tools for optimization of treatment for newly diagnosed elderly multiple myeloma patients.

NCT ID: NCT02918279 Completed - Obesity Clinical Trials

Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity

Start date: September 29, 2016
Phase: Phase 3
Study type: Interventional

This trial is conducted globally. The aim of this trial is to investigate the effect of liraglutide for weight management in pubertal adolescent subjects with obesity.